Bovine herpesvirus type 1 as a novel oncolytic virus

Area of Science:

• Oncolytic virotherapy
• Cancer gene therapy
• Virology

Background:

• Oncolytic virotherapy utilizes viruses to target and destroy cancer cells.
• Current oncolytic viruses are engineered human viruses or naturally oncotropic nonhuman viruses.
• Defects in innate immune pathways, like the type 1 interferon (IFN) pathway, are often exploited for tumor cell targeting.

Purpose of the Study:

• To investigate Bovine herpesvirus type 1 (BHV-1) as a novel oncolytic virus candidate.
• To determine BHV-1's replication and cell-killing capabilities in human tumor cells.
• To explore the mechanism of BHV-1's tumor targeting, particularly its interaction with the IFN pathway.

Main Methods:

• BHV-1 infection and replication assays in normal and transformed human cell lines.
• Analysis of IFN production (mRNA and protein) following BHV-1 infection.
• Assessment of human antibody and serum neutralization capacity against BHV-1 and HSV-1.

Main Results:

• BHV-1 efficiently infects and kills various immortalized and transformed human cell types.
• BHV-1 infection of human cells does not elicit a detectable type 1 interferon response.
• Human sera with neutralizing capacity against HSV-1 showed limited neutralization of BHV-1.

Conclusions:

• BHV-1 is a promising novel oncolytic virus candidate for cancer gene therapy.
• BHV-1 exhibits distinct tumor targeting mechanisms independent of defects in IFN pathways.
• BHV-1's species-specificity and lack of pre-existing human neutralizing antibodies contribute to its potential efficacy.